Online inquiry

IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15194MR)

This product GTTS-WQ15194MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Crohn's disease (CD), Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ15194MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10368MR IVTScrip™ mRNA-Anti-APP, LY2062430(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY2062430
GTTS-WQ13853MR IVTScrip™ mRNA-Anti-GCGR, REGN-1193(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA REGN-1193
GTTS-WQ3197MR IVTScrip™ mRNA-Anti-ANPEP, ARENEGYR(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ARENEGYR
GTTS-WQ9393MR IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Interleukin 2
GTTS-WQ11746MR IVTScrip™ mRNA-Anti-IGF1R, MK-0646(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MK-0646
GTTS-WQ4623MR IVTScrip™ mRNA-Anti-LAG3, BMS-986016(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-986016
GTTS-WQ9907MR IVTScrip™ mRNA-Anti-CSF2, KB-003(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA KB-003
GTTS-WQ79MR IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA (131)I-chTNT-1/B
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW